BerGenBio to present at ASCO 2016

Researchers involved in BerGenBio’s BGBC003 clinical trial of BGB324, a highly selective inhibitor of Axl, in patients with AML and high-risk MDS will be presenting a poster entitled “A first-in-patient phase I study of BGB324, a selective Axl kinase inhibitor in patients with refractory/relapsed AML and high-risk MDS” during this year’s ASCO Annual Meeting.
Sunday June 5, 8:00 AM to 11:30 AM
Abstract No:
2561
Poster Board Number:
Poster Session (Board #261)
Citation:
J Clin Oncol 34, 2016 (suppl; abstr 2561)